SNO 2021: Apparent Benefits of Toca FC in Recurrent HGG Continue for an Average of 49.2 Months
The agent is an investigational nonlytic, retroviral-replicating vector.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Brain Cancer Center of Excellence
Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.